Pieris and Pfizer (formerly Seagen) Immuno-Oncology Collaboration

This collaboration aims to investigate several targeted, bispecific immuno-oncology treatments for solid tumors and blood cancers. Together, we will develop antibody-Anticalin fusion proteins that leverages Pieris’ suite of agonistic costimulatory Anticalin proteins and Pfizer’s portfolio of cancer targets and tumor-specific antibodies. The bispecific drugs will be designed to activate a patient’s immune cells locally in the tumor microenvironment.